The estimated Net Worth of Norman David Eansor is at least 3.64 百万$ dollars as of 12 November 2021. Mr Eansor owns over 27,958 units of Bio-Techne Corp stock worth over 155,578$ and over the last 21 years he sold TECH stock worth over 1,884,382$. In addition, he makes 1,598,732$ as Pres of Protein Sciences Segment at Bio-Techne Corp.
Mr has made over 14 trades of the Bio-Techne Corp stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 27,958 units of TECH stock worth 3,496,148$ on 12 November 2021.
The largest trade he's ever made was exercising 32,933 units of Bio-Techne Corp stock on 5 February 2021 worth over 3,510,328$. On average, Mr trades about 3,534 units every 65 days since 2003. As of 12 November 2021 he still owns at least 2,117 units of Bio-Techne Corp stock.
You can see the complete history of Mr Eansor stock trades at the bottom of the page.
Norman David Eansor is the Pres of Protein Sciences Segment at Bio-Techne Corp.
As the Pres of Protein Sciences Segment of Bio-Techne Corp, the total compensation of Mr Eansor at Bio-Techne Corp is 1,598,732$. There are 7 executives at Bio-Techne Corp getting paid more, with Charles Kummeth having the highest compensation of 11,483,800$.
Mr Eansor is 59, he's been the Pres of Protein Sciences Segment of Bio-Techne Corp since . There are 8 older and 9 younger executives at Bio-Techne Corp. The oldest executive at Bio-Techne Corp is Roeland Nusse, 70, who is the Independent Director.
Norman's mailing address filed with the SEC is 8100 Southpark Way, Littleton, CO 80120, USA.
Over the last 22 years, insiders at Bio-Techne Corp have traded over 37,160,097$ worth of Bio-Techne Corp stock and bought 4,361 units worth 454,370$ . The most active insiders traders include Charles R. Kummeth、Rupert Vessey、John L Higgins. On average, Bio-Techne Corp executives and independent directors trade stock every 23 days with the average trade being worth of 964,850$. The most recent stock trade was executed by Kim Kelderman on 29 August 2024, trading 1,492 units of TECH stock currently worth 99,919$.
bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.
Bio-Techne Corp executives and other stock owners filed with the SEC include: